Banner - injectconnect

injectConnect

The wholesale acquisition cost (WAC) of Injectafer is $1,074.25 per infusion.* Actual costs may vary based on insurance coverage and eligibility for support programs.

*WAC is the price at which Daiichi Sankyo sells its products to wholesalers.

So you can support your patients, Daiichi Sankyo Access Central offers multiple resources to guide you through the reimbursement process and find help for eligible patients to afford their Injectafer treatment.

DSI Logo

IV IRON Hotline

1-877-4-IV-IRON

For timely assistance over the phone, the IV Iron Hotline is available
Monday through Friday, between 9:00 am and 8:00 pm ET.
Call for help with reimbursement, verification, coding, and more.


Coverage and Access Support


Coverage and Access Support

Specialists and resources are available to help with insurance verifications, billing and coding, and claims appeals.

Learn more at Daiichi Sankyo
Access Central


Financial Assistance


Financial Assistance

Daiichi Sankyo Access Central offers financial assistance for eligible patients prescribed Injectafer.

Learn more at Daiichi Sankyo
Access Central


Helpful Resources


Helpful Resources

Tools and forms to assist with reimbursement and patient support for Injectafer.

Learn more at Daiichi Sankyo
Access Central

Patient information will be kept strictly confidential at all times.

Every attempt is made to provide accurate, up-to-date information. The IV Iron Reimbursement Hotline cannot guarantee successful reimbursement.

This information is not intended to provide legal, medical, or other professional advice. This information is provided as reference only. Daiichi Sankyo, Inc. makes no representations or guarantees regarding the completeness or accuracy of this information and has no obligation to update this information to reflect changes in laws that may affect reimbursement for Injectafer. For assistance with legal or medical issues, you are urged to consult a qualified professional.

Important Safety Information

INDICATIONS

Injectafer® (ferric carboxymaltose injection) is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, and in adult patients with non-dialysis dependent chronic kidney disease.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Injectafer is contraindicated in patients with hypersensitivity to Injectafer or any of its inactive components.

WARNINGS AND PRECAUTIONS

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Injectafer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Injectafer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. In clinical trials, serious anaphylactic/anaphylactoid reactions were reported in 0.1% (2/1775) of subjects receiving Injectafer. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but were not limited to, pruritus, rash, urticaria, wheezing, or hypotension were reported in 1.5% (26/1775) of these subjects.

In clinical studies, hypertension was reported in 3.8% (67/1775) of subjects. Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed in 6% (106/1775) of subjects. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Injectafer administration.

In the 24 hours following administration of Injectafer, laboratory assays may overestimate serum iron and transferrin bound iron by also measuring the iron in Injectafer.

ADVERSE REACTIONS

In two randomized clinical studies, a total of 1775 patients were exposed to Injectafer, 15 mg/kg of body weight, up to a single maximum dose of 750 mg of iron on two occasions, separated by at least 7 days, up to a cumulative dose of 1500 mg of iron. Adverse reactions reported by ≥2% of Injectafer-treated patients were nausea (7.2%); hypertension (3.8%); flushing/hot flush (3.6%); blood phosphorus decrease (2.1%); and dizziness (2.0%).

The following serious adverse reactions have been most commonly reported from the post-marketing spontaneous reports: urticaria, dyspnea, pruritus, tachycardia, erythema, pyrexia, chest discomfort, chills, angioedema, back pain, arthralgia, and syncope.

To report adverse events, please contact American Regent at 1-800-734-9236. You may also contact the FDA at www.fda.gov/medwatch or 1-800-FDA-1088.

Please see Full Prescribing Information.